- Novo Nordisk has launched an updated formulation of Rybelsus® (semaglutide tablets) in Canada, offering the same established clinical profile in smaller tablets and lower dose strengths for adults with type 2 diabetes.
- The optimized formulation improves semaglutide absorption, allowing 1.5 mg, 4 mg, and 9 mg tablets to deliver effects equivalent to the original 3 mg, 7 mg, and 14 mg doses, respectively.
- Health Canada’s authorization was supported by a bioequivalence study involving 546 healthy participants, which demonstrated comparable semaglutide exposure, safety, efficacy, and administration to the original formulation.
- Rybelsus remains the first and only GLP-1 tablet approved in Canada, providing adults with type 2 diabetes an oral treatment option that may offer greater convenience while maintaining established clinical benefits.
Takeaways:
Novo Nordisk’s updated Rybelsus in Canada is a smaller-tablet, lower-milligram GLP-1 formulation that delivers the same clinical effect as the original 3/7/14 mg doses, with 1.5/4/9 mg tablets now bioequivalent and approved by Health Canada. This improves dosing precision and patient convenience while maintaining the established GLP-1 efficacy of oral semaglutide, keeping Rybelsus as Canada’s only approved GLP-1 tablet.
Source: CA Newswire
